In a major relief to drug firm Wockhardt, its Chikalthana plant at Aurangabad in Maharashtra has received a good manufacturing practice cer...

Shares of drug firm Wockhardt today surged 3 per cent after the company said the UK health regulator MHRA has completed inspection of its p...

The stock jumped 3.65% to hit a high of Rs 1,597.15 on the exchange. Still, the stock is trading 20% lower from its all-time high of Rs 2,0...

Wockhardt said the UK health regulator has completed inspection of its plant at Chikalthana without issuing any critical observations on th...

Wockhardt, which has been under the USFDA's scanner, today said that the American health regulator has completed the inspection of its Walu...

Wockhardt Ltd closed the day on BSE at Rs 1,575.05; up 10.67%. The stock surged as much as 11.57 per cent in intraday trade after reports t...

When contacted, Wockhardt Chairman Habil Khorakiwala said the total number of drugs that are recalled in the US is 13.

The FDA banned US exports from Wockhardt's Waluj and Chikalthana plants in central India in 2013, citing manufacturing quality lapses.

US Food and Drug Administration conducted inspection for about a week, he said there were no serious observation and nothing on data integr...

UK drug regulator cleared its Chikalthana facility; the company has also resolved its compliance-related issues at the Illinois facility.

Fundamental troubles or the regulatory problems are not going to go away in a hurry for Wockhardt and it has become more of a trading stock...

The USFDA import alert on Wockhardt's second plant will have a negative impact on the pharma major, say brokerages.

In May, the USFDA had also issued an import alert on the company's Waluj facility which makes injectables and solid dosages.

The Chikalthana facility received ‘483’ observations after the USFDA raised several concerns. This is the second plant in India to get impo...

UKMHRA had imposed restrictions on import of medicines made at the Mumbai-based firm's unit at Kadaiya for violation of norms.

The stock is now locked in lower circuit at Rs 499.30. It has lost nearly 10% in the month of October as compared to over 60% fall so far i...

The impact of the same on existing business will only be known once the company receives further communication from UKMHRA, Wockhardt said.